Nuveen
RLAY icon

Nuveen’s Relay Therapeutics RLAY Stock Holding History

Nuveen’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.35M Buy
392,691
+90,495
+30% +$1.31M ﹤0.01% 1887
2026
Q1 		$3.01M Buy
302,196
+1,732
+0.6% +$15.5K ﹤0.01% 2107
2025
Q4 		$2.54M Buy
300,464
+12,014
+4% +$85.7K ﹤0.01% 2188
2025
Q3 		$1.51M Hold
288,450
– – ﹤0.01% 2421
2025
Q2 		$998K Sell
288,450
-31,945
-10% -$95K ﹤0.01% 2605
2025
Q1 		$839K Sell
320,395
-333,033
-51% -$1.3M ﹤0.01% 2712
2024
Q4 		$2.69M Buy
653,428
+378,322
+138% +$2.06M ﹤0.01% 2259
2024
Q3 		$1.95M Sell
275,106
-171,702
-38% -$1.28M ﹤0.01% 2424
2024
Q2 		$2.91M Buy
446,808
+184,925
+71% +$1.26M ﹤0.01% 2199
2024
Q1 		$2.17M Hold
261,883
– – ﹤0.01% 2367
2023
Q4 		$2.88M Buy
261,883
+3,413
+1% +$28.8K ﹤0.01% 2239
2023
Q3 		$2.17M Sell
258,470
-1,612
-0.6% -$17.3K ﹤0.01% 2264
2023
Q2 		$3.27M Buy
260,082
+9,145
+4% +$114K ﹤0.01% 2121
2023
Q1 		$4.13M Buy
250,937
+15,734
+7% +$282K ﹤0.01% 1996
2022
Q4 		$3.51M Sell
235,203
-38,975
-14% -$746K ﹤0.01% 2114
2022
Q3 		$6.13M Buy
274,178
+4,332
+2% +$95.1K ﹤0.01% 1779
2022
Q2 		$4.52M Buy
269,846
+52,523
+24% +$1.13M ﹤0.01% 2011
2022
Q1 		$5.63M Buy
217,323
+5,272
+2% +$128K ﹤0.01% 1995
2021
Q4 		$5.93M Sell
212,051
-2,167
-1% -$68.5K ﹤0.01% 2025
2021
Q3 		$7.95M Buy
214,218
+6,707
+3% +$226K ﹤0.01% 1944
2021
Q2 		$7.59M Buy
207,511
+50,977
+33% +$1.68M ﹤0.01% 2020
2021
Q1 		$5.41M Buy
156,534
+27,843
+22% +$1.21M ﹤0.01% 2135
2020
Q4 		$5.35M Buy
128,691
+2,652
+2% +$120K ﹤0.01% 2039
2020
Q3 		$5.37M Buy
+126,039
New +$4.81M ﹤0.01% 1879

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Nuveen's RLAY Position: Q2 2026 in Review

Nuveen increased its Relay Therapeutics (RLAY) stake by 30% in Q2 2026, buying an estimated $1.31M and bringing the position to 392,691 shares worth $7.35M. The position accounts for ﹤0.01% of the portfolio, ranked #1887.

Nuveen first reported a position in RLAY in Q3 2020 and has held it in 24 quarters since. The position peaked at $7.95M in Q3 2021. 258 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Nuveen held 392,691 shares of Relay Therapeutics worth $7.35M as of Q2 2026.
  • Nuveen bought 90,495 Relay Therapeutics shares in Q2 2026, an estimated $1.31M.
  • Relay Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #1887 holding.
  • Nuveen first reported a position in Relay Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • Nuveen's Relay Therapeutics position peaked at $7.95M in Q3 2021.
  • 258 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.